Agreement set to speed DUB compounds discovery

software, RubDUB, to accelerate its search for novel deubiquitinase (DUB) modulating compounds required for the development of DUB inhibitors, DUB-targeting PROTACs and DUB-Targeting Chimeras (DUBTACs). Alleo will use Ubiquigent’s platforms and expertise to advance its in-house DUB-focused precision neuroscience programmes, with the partners also planning to work jointly with third parties seeking to develop DUB-modulating therapeutics.

Ubiquigent, a respected partner in the drug discovery field, has an evolving track record in the development of novel DUB targeting compounds. Alleo Labs’ lead program, ALO-001, is a potential first-in-class, oral, brain-penetrant DUB small molecule inhibitor designed to address neuroinflammation in Parkinson's and Alzheimer's diseases and is currently in preclinical development with plans for first-in-human clinical trials.

Jason Mundin, MBA, CEO of Ubiquigent, commented: “The potential for the development of novel DUB-targeting therapeutics has never been greater, and this partnership with Alleo presents an exciting opportunity to not only add additional support to our in-house programmes prior to partnering, but also those of the partners we are supporting. We look forward to working with the team at Alleo and combining our approaches to further accelerate DUB-focused drug discovery.”

Jermaine Ross, Ph.D, co-founder and CEO of Alleo, commented: “We are on the brink of a new era in understanding the role of DUBs in common neurological diseases. Our partnership with Ubiquigent provides a strategic advantage by connecting us with leading experts in the field. This collaboration not only enhances our capabilities through access to Ubiquigent’s platform, but also synergises with our own drug discovery platform. Together, we will significantly accelerate our efforts to advance DUB-focused therapies to the clinic. We are thrilled to work with the team at Ubiquigent on this promising opportunity.”

More information online